ROCKVILLE, Md., July 6, 2016 /PRNewswire/ -- Synthetic
Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused
on developing therapeutics to protect the gut microbiome while
targeting pathogen-specific diseases, announced today that
Jeffrey Riley, President & Chief
Executive Officer, is scheduled to present at the 2nd
Annual Cantor Fitzgerald Annual Healthcare Conference being held
July 12-13 at Le Parker Meridien in
New York, NY. Mr. Riley is
scheduled to present on Wednesday, July 13,
2016 at 3:00 p.m. ET.
A live webcast of Synthetic Biologics' presentation may be
accessed by logging onto the web at
http://wsw.com/webcast/cantor4/syn. After the presentation, a
replay will be archived and accessible for 90 days at the same
website.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a clinical stage
company developing therapeutics to protect the gut microbiome while
targeting pathogen-specific diseases. The Company's lead candidates
in Phase 2 development are: (1) SYN-010 which is intended to reduce
the impact of methane producing organisms in the gut microbiome to
treat an underlying cause of irritable bowel syndrome with
constipation (IBS-C), and (2) SYN-004 which is designed to protect
the gut microbiome from the effects of certain commonly used
intravenous (IV) beta-lactam antibiotics for the prevention of
C. difficile infection and antibiotic-associated diarrhea
(AAD). The Company is also developing preclinical stage
monoclonal antibody therapies for the prevention and treatment of
pertussis and novel discovery stage biotherapeutics for the
treatment of phenylketonuria (PKU). For more information, please
visit Synthetic Biologics' website at
www.syntheticbiologics.com.
Logo - http://photos.prnewswire.com/prnh/20160105/319502LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/synthetic-biologics-to-present-at-the-2nd-annual-cantor-fitzgerald-healthcare-conference-300294096.html
SOURCE Synthetic Biologics, Inc.